STOCK TITAN

GUIDED THERAPEUTCS INC - $GTHP STOCK NEWS

Welcome to our dedicated page for GUIDED THERAPEUTCS news (Ticker: $GTHP), a resource for investors and traders seeking the latest updates and insights on GUIDED THERAPEUTCS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GUIDED THERAPEUTCS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GUIDED THERAPEUTCS's position in the market.

Rhea-AI Summary
Guided Therapeutics, Inc. (GTHP) announces final stages of clinical data report for LuViva Advanced Cervical Scan approval in China. Expected approval by Chinese NMPA with positive feedback from prominent doctors. Commercialization payments from Chinese partner to exceed $4 million in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
-
Rhea-AI Summary
Guided Therapeutics, Inc. (OTCQB: GTHP) announced the completion of a clinical trial for marketing and sales approval of the LuViva Advanced Cervical Scan by the Chinese National Medical Products Administration (NMPA). The study, involving about 450 women, was conducted at prestigious medical institutions, including Shandong University, Fudan University, and Peking University. The study was led by prominent doctors, and the results will be filed with NMPA within the next 90 days, triggering purchase order payments to Guided Therapeutics of approximately $2.2 million, with more significant orders expected in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.41%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
GUIDED THERAPEUTCS INC

OTC:GTHP

GTHP Rankings

GTHP Stock Data

5.09M
23.73M
43.7%
7.34%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Norcross

About GTHP

1